THOUSAND OAKS, Calif.--(BUSINESS WIRE)--Aug. 10, 2005--Amgen
(NASDAQ:AMGN), a leading human therapeutics company in the
biotechnology industry, today announced the appointment of Michael
Kelly as vice president, Corporate Planning and Control, and chief
accounting officer. Kelly, formerly vice president, Finance for
Process Development, Operations and Quality at Amgen, will report to
Richard Nanula, executive vice president and chief financial officer.
Kelly replaces Timothy Martin as Amgen´s chief accounting officer.
Martin is taking on new responsibilities as Amgen´s vice president,
Finance for Global Commercial Operations.
Kelly joined Amgen in early 2003 as vice president, Finance. From
2000 to 2002, Mr. Kelly was vice president, Finance and chief
financial officer at Tanox, Inc., and from 1998 to 2000, he served as
corporate controller at Biogen, Inc. From 1981 to 1998, Mr. Kelly
progressed through positions of increasing responsibility in finance
at Monsanto Life Sciences Company and its subsidiaries ending his
tenure as vice president, Finance with the Nutrition and Consumer
Kelly earned a B.S. in Business Administration from Florida A&M
Amgen discovers, develops and delivers innovative human
therapeutics. A biotechnology pioneer since 1980, Amgen was one of the
first companies to realize the new science´s promise by bringing safe
and effective medicines from lab, to manufacturing plant, to patient.
Amgen therapeutics have changed the practice of medicine, helping
millions of people around the world in the fight against cancer,
kidney disease, rheumatoid arthritis, and other serious illnesses.
With a broad and deep pipeline of potential new medicines, Amgen
remains committed to advancing science to dramatically improve
people´s lives. To learn more about our pioneering science and our
vital medicines, visit www.amgen.com.
CONTACT: Amgen, Thousand Oaks
Christine Cassiano, 805/447-4587 (Media)
Arvind Sood, 805-447-1060 (investors)